Can Pentoxifylline Improve Long-term Outcomes In Preterm Infants With Late-onset Sepsis Or Necrotizing Enterocolitis – A Pragmatic, Randomized, Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$2,901,130.00
Summary
Very preterm infants are at high risk of death and disability. Brain injury is often the result of inflammation caused by infection or bowel disease. To date, there is no treatment to reduce the harmful effects of inflammation. Pentoxifylline reduces inflammation and is a promising, safe and inexpensive treatment option for preterm infants. This study will determine whether Pentoxifylline in addition to antibiotics improves survival without disability in preterm infants.
Improving The Treatment Of Neonatal Sepsis Through Vancomycin Pharmacokinetic And Pharmacodynamic Modelling
Funder
National Health and Medical Research Council
Funding Amount
$71,458.00
Summary
Our study will assess whether vancomycin, a key antibiotic used to treat severe infections in young infants, is best given as a continuous infusion or as multiple doses per day. We will determine which is the most effective method to achieve the target blood level of vancomycin and if current recommended target levels for vancomycin are appropriate for infants. Findings will be used to develop a bedside tool that will enable clinicians to tailor the dose of vancomycin to individual children.
Modified Peanut Allergen Combined With A Novel Dietary Adjuvant As A Cure For Peanut Allergy: A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,130,021.00
Summary
Peanut allergy is common and there is no cure. Current studies of peanut immunotherapy have shown the effects are not generally long lasting with many side effects. We plan to study a novel form of oral peanut immunotherapy using modified peanut and a dietary fibre (modified starch) supplement. We have evidence that modified peanut may work to desensitise patients with less side effects and that the diet supplement protects animals from developing food allergy.
Strategies To Reduce The Burden Of Gastroenteritis In Aboriginal Children.
Funder
National Health and Medical Research Council
Funding Amount
$124,676.00
Summary
Rotavirus is the leading cause of severe gastroenteritis in children. Despite early promise, vaccines which target rotavirus seem to be less effective in low-resource settings and also amongst Australian Indigenous children. This study seeks to assess whether an extra dose of rotavirus vaccine (RV1) will improve the effectiveness of rotavirus vaccine in Aboriginal children and result in decreased admissions and clinic visits in the first three years of life.
Randomised Controlled Trial Of The Use Of Nitazoxanide Versus Placebo To Treat Gastroenteritis Among Aboriginal Children
Funder
National Health and Medical Research Council
Funding Amount
$1,324,808.00
Summary
Better treatment strategies are needed for Indigenous children with gastroenteritis. At present, most treatment is supportive only, with little effect on the duration of symptoms. Nitazoxanide appears to have effects on a broad range of pathogens which cause gastroenteritis, but it is not clear whether it will be of benefit in this population. We will compare the speed of symptom resolution in children who receive nitazoxanide with a group who receive a placebo instead.
Does Bovine Lactoferrin Prevent Death Or Disability In Very Low Birthweight Infants? Childhood Follow Up In The NHMRC LIFT Study
Funder
National Health and Medical Research Council
Funding Amount
$1,474,012.00
Summary
Our international consortium of investigators proposes to undertake follow up in survivors among 1,500 very low birth weight preterm infants enrolled in the NHMRC Lactoferrin Infant Feeding Trial, which is designed to evaluate whether low-cost oral lactoferrin supplementation reduces death and disability in early childhood.
Improving The Quantity, Quality, Relevance And Conduct Of Clinical Trials Of Medicines In Children.
Funder
National Health and Medical Research Council
Funding Amount
$102,576.00
Summary
I am a specialist clinical trials pharmacist focussed on the challenges associated with the conduct of medicinal trials in children. My intention is to collect evidence to determine the best strategies for improving the quantity, quality and relevance of clinical trials in children. This will help to ensure safe and effective age-appropriate drug therapies for children and improve the health outcomes of our children.